Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | AMY2A | P04746 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | FGF1 | P05230 | 1/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.33 |
| ▸ | LRAT | O95237 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | PYGB | P11216 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GJA1 | P17302 | 1/20 | 0.31 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21122324 | 1.00 | OGA (0.39) | OGAAMY2ALGALS8SLC5A2MEN1 | |
| SCHEMBL13563735 | 1.00 | OGA (0.39) | OGAAMY2ALGALS8SLC5A2MEN1 | |
| SCHEMBL21530603 | 1.00 | OGA (0.39) | OGAAMY2ALGALS8SLC5A2MEN1 | |
| SCHEMBL11915783 | 1.00 | OGA (0.39) | OGAAMY2ALGALS8SLC5A2MEN1 | |
| SCHEMBL26170073 | 0.89 | MEN1 (0.46) | AMY2AMEN1AMY1ALRATTRPV1 | |
| SCHEMBL20067007 | 0.89 | MEN1 (0.46) | AMY2AMEN1AMY1ALRATTRPV1 | |
| SCHEMBL26736014 | 0.88 | AMY2A (0.51) | AMY2ALGALS8MEN1AMY1ALRAT | |
| SCHEMBL19631197 | 0.86 | LGALS8 (0.41) | OGALGALS8MEN1FGF1PYGB | |
| SCHEMBL19631324 | 0.86 | LGALS8 (0.41) | OGALGALS8MEN1FGF1PYGB | |
| SCHEMBL19326923 | 0.86 | MEN1 (0.33) | OGALGALS8MEN1AMY1ALRAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240243287-A1 | NEGATIVE ELECTRODE ACTIVE MATERIAL MODIFIED BY ZWITTERIONIC POLYMER, AND PREPARATION METHOD AND APPLICATIONS THEREOF | BBL Technology Corporation (TW) | 2024-07-18 | — | — | US | disclosed |
| US-20240216531-A1 | CHITOSAN-CONTAINING NANOPARTICLES FOR DELIVERY OF POLYNUCLEOTIDES | VALORISATION RECH HSCM LIMITED PARTNERSHIP (CA) | 2024-07-04 | — | — | US | disclosed |
| US-20230022614-A1 | POLYMERIC FATTY ACID SALT COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID-BASED SUBSTRATES, ESPECIALLY HAIR | MOMENTIVE PERFORMANCE MAT GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| EP-2849791-B1 | CONJUGATE OF A PHOTOSENSITISER AND CHITOSAN AND USES THEREOF | PCI BIOTECH AS (NO) | 2018-07-04 | — | — | EP | disclosed |
| US-9901636-B2 | Conjugate of a photosensitiser and chitosan and uses thereof | PCI BIOTECH AS (NO) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022614-A1 | POLYMERIC FATTY ACID SALT COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID-BASED SUBSTRATES, ESPECIALLY HAIR | DAO, ELOVL3, ELOVL6 | OGA 459/4885AMY2A 4273/4885LGALS8 3236/4885 |
| US-20240216531-A1 | CHITOSAN-CONTAINING NANOPARTICLES FOR DELIVERY OF POLYNUCLEOTIDES | TLR3, PCNP, H1-3 | OGA 2013/4885AMY2A 4225/4885LGALS8 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.